Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 6
2005 11
2006 10
2007 12
2008 3
2009 8
2010 12
2011 9
2012 2
2013 6
2014 13
2015 12
2016 25
2017 20
2018 19
2019 14
2020 21
2021 23
2022 19
2023 18
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Results by year

Filters applied: . Clear all
Page 1
KRAS Allelic Variants in Biliary Tract Cancers.
Moffat GT, Hu ZI, Meric-Bernstam F, Kong EK, Pavlick D, Ross JS, Murugesan K, Kwong L, De Armas AD, Korkut A, Javle M, Knox JJ. Moffat GT, et al. Among authors: javle m. JAMA Netw Open. 2024 May 1;7(5):e249840. doi: 10.1001/jamanetworkopen.2024.9840. JAMA Netw Open. 2024. PMID: 38709532 Free PMC article.
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma.
Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, Xiao L, Murugesan K, Danziger N, Pavlick D, Korkut A, Ross JS, Javle M. Makawita S, et al. Among authors: javle m. JCO Precis Oncol. 2024 Mar;8:e2300544. doi: 10.1200/PO.23.00544. JCO Precis Oncol. 2024. PMID: 38547421
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study.
Nelson BE, Roszik J, Ahmed J, Barretto CMN, Nardo M, Campbell E, Johnson AM, Piha-Paul SA, Oliva ICG, Weathers SP, Cabanillas M, Javle M, Meric-Bernstam F, Subbiah V. Nelson BE, et al. Among authors: javle m. Mol Cancer. 2024 Mar 26;23(1):64. doi: 10.1186/s12943-024-01982-4. Mol Cancer. 2024. PMID: 38532456 Free PMC article.
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri TP, Evans KW, Wang B, Zhao M, Akcakanat A, Raso MG, Rizvi YQ, Zheng X, Korkut A, Varadarajan K, Uzunparmak B, Dumbrava EE, Pant S, Ajani JA, Pohlmann PR, Jensen VB, Javle M, Rodon J, Meric-Bernstam F. DiPeri TP, et al. Among authors: javle m. Cancer Discov. 2024 May 1;14(5):828-845. doi: 10.1158/2159-8290.CD-23-0838. Cancer Discov. 2024. PMID: 38358339 Free PMC article. Clinical Trial.
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.
Ngoi NYL, Tang TY, Gaspar CF, Pavlick DC, Buchold GM, Scholefield EL, Parimi V, Huang RSP, Janovitz T, Danziger N, Levy MA, Pant S, De Armas AD, Kumpula D, Ross JS, Javle M, Ahnert JR. Ngoi NYL, et al. Among authors: javle m. Oncologist. 2024 Feb 8:oyae011. doi: 10.1093/oncolo/oyae011. Online ahead of print. Oncologist. 2024. PMID: 38330461 Free article.
Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.
Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Nowlen CJ, et al. Among authors: javle m. J Immunother Precis Oncol. 2024 Feb 5;7(1):7-17. doi: 10.36401/JIPO-23-2. eCollection 2024 Feb. J Immunother Precis Oncol. 2024. PMID: 38327755 Free PMC article.
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Amaria R, et al. Among authors: javle m. J Immunother Cancer. 2024 Feb 2;12(2):e006822. doi: 10.1136/jitc-2023-006822. J Immunother Cancer. 2024. PMID: 38309721 Free PMC article.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA, Xu B, Dumbrava EE, Fu S, Karp DD, Meric-Bernstam F, Hong DS, Rodon JA, Tsimberidou AM, Raghav K, Ajani JA, Conley AP, Mott F, Fan Y, Fan J, Peng P, Wang H, Ni S, Sun C, Qiang X, Levin WJ, Ngo B, Ru QC, Wu F, Javle MM. Piha-Paul SA, et al. Among authors: javle mm. Oncologist. 2024 Apr 4;29(4):e514-e525. doi: 10.1093/oncolo/oyad338. Oncologist. 2024. PMID: 38297981 Free PMC article. Clinical Trial.
Revisiting the Malignant Masquerade at the Liver Hilum: Have We Made Progress?
Jain AJ, Lendoire M, Boyev A, Newhook TE, Tzeng CD, Tran Cao HS, Coronel E, Lee SS, Hu ZI, Javle M, Lee JH, Vauthey JN, Chun YS. Jain AJ, et al. Among authors: javle m. Ann Surg Oncol. 2024 May;31(5):3062-3068. doi: 10.1245/s10434-024-14939-0. Epub 2024 Jan 28. Ann Surg Oncol. 2024. PMID: 38282027
244 results